



Society for CSF Analysis
and Clinical Neurochemistry

Preliminary program

3rd meeting of the Society for CSF analysis and
clinical neurochemistry

30th June and 1st of July 2022



Venue:
Kaiserin-Friedrich-Stiftung,
Berlin



Society for CSF Analysis
and Clinical Neurochemistry



www.neurochem.info

Dear colleagues,

we would like to invite you to our third general meeting of our „Society for CSF analysis and clinical neurochemistry“. Within this meeting we try to cover most recent neurochemical findings in neurodegenerative and inflammatory diseases and also including a session on psychiatric diseases. Technical developments and standardization are also specifically addressed.

In our last meeting in Amsterdam the short oral presentations of selected posters have represented one of the most appreciated feature of our meeting.

Therefore, we further valorized this part of the program by including some slots for longer talks based on abstract selection.

We hope that we could gain your interest and that you will come to Berlin.

For the society


Kay Blennow, President

Lucilla Parnetti, Vice President

Charlotte Teunissen, Vice President

Markus Otto, Treasurer

3rd meeting of the Society for CSF analysis and clinical neurochemistry



Advisory board:

Sebastiaan Engelborghs, Sanna Kaisa Herruka, Michael Khalil, Jens Kuhle, Sylvain Lehmann, Piotr Lewczuk, Alberto Lleo, Armand Perret Liaudet, Hayrettin Tumani, Martin Turner, Marcel Verbeek, Jens Wiltfang, Henrik Zetterberg

Local organizing committee:

Markus Otto, Hayrettin Tumani, Klemens Ruprecht



www.neurochem.info

Thursday June 30th

Symposium Program

- 08.30 Come together and coffee
- 09.00 **Welcome**
Markus Otto (Germany)
- Chairs of the keynotes**
Hayrettin TUMANI (Germany), Klemens Ruprecht (Germany)
- 09.15 – 09.45 **Keynote: From utopia to reality, development of novel blood based biomarkers for various neurological diseases.**
Kaj Blennow (Sweden)
- 09.45 – 10.15 **Keynote: Biomarkers for trials and therapy response**
Charlotte Teunissen (Netherlands)
- 10.15 – 10.45 **Coffee break**
- 10.45 – 11.30 **Symposium – Autoimmune disorders**
Chairs: Brigitte Wildemann (Germany), Michael Khalil (Austria)
- 10:50 – 11:10 Peripheral Neuropathies: Luuk Wieske (Netherlands)
- 11:10 – 11:30 Autoimmune encephalitis: Lorenzo Gaetani (Italy)
- 11:30 – 11:40 Plasma NFL chain levels suggest Neuroprotection following therapeutic remyelination in people with MS: Ahmed Abdelhak (USA)
- 11:40 – 11:50 The clinical relevance of CSF sphingomyelin dosage: a new myelin biomarker in immune-mediated demyelinating neuropathies: Giovanna Capodivento (Italy)
- 12:00 – 13.00 **Symposium – neurodegeneration meets neuroinflammation**
Parkinson and MS
Chairs: Marcel Verbeek (Netherlands), Sanna-Kaisa Herruka (Finland)
- 12:00 – 12:20 Parkinsonian syndromes (DLB, MSA): Wilma van den Berg (Netherlands)
- 12:20 – 12:40 MS: Jens Kuhle (Switzerland)
- 12:40 – 12:50 CSF proteome profiling reveals novel specific diagnostic biomarkers for Dementia with Lewy bodies: Marta Del Campo (Spain)
- 12:50 – 13:00 Cerebrospinal fluid proenkephalin and prodynorphin levels in Huntington's and Parkinson's disease: Samir Abu-Rumeileh (Germany)
- 13.00 – 13.30 **Lunch break**

- 13.30 – 14.30 **Poster session** (Lucilla Parnetti, Italy, Markus Otto, Germany)
- 14.30 – 15.45 **Symposium Beta-amyloid and prion plaques – Alzheimer and Creutzfeldt-Jakob diseases**
Focus novel (non-Abeta, ptau, NfL) biomarkers, such as pentraxin, VGF, Ng, prion and Abeta oligomers or seeds
Chairs: Sebastiaan Engelborghs (Belgium), Ines Baldeiras (Portugal)
- 14.30 – 14.50 AD: Oskar Hansson (Sweden)
- 14.50 – 15.10 CJD: Piero Parchi (Italy)
- 15.10 – 15.20 Evaluating plasma glial fibrillary acidic protein, neurofilament light, phosphorylated-tau-181 and amyloid β 42/40 as prognostic biomarkers for clinical progression to dementia in individuals with subjective cognitive decline and mild cognitive impairment: Maddy Honey (Netherlands)
- 15.20 – 15.40 Synaptic biomarkers in the cerebrospinal fluid associate differentially with classical neuronal biomarkers and reflect diverse pathologies: Shreyasee Das (Belgium)
- 15.40 – 16.10 **Coffee break**
- 16.10 – 17.25 **Symposium: How to accelerate biomarker development?**
Chairs: Henrik Zetterberg (Sweden), Milica Kramberger (Slovenia)
- 16.10 – 16.30 MIRIADE - introduction: Eline Willems (Netherlands)
- 16.30 – 16.50 Modern approaches in biomarker data analysis for biomarker identification: Lisa Vermunt (Netherlands)
- 16.50 – 17.10 EMA perspective - Implementation and reimbursement: Maria Tome (Spain)
- 17.10 – 17.30 Discussion: Henrik Zetterberg (Sweden)
- 17.30 - 18.00 **Break**
- 18.00 - 19.00 Society meeting (Kaj Blennow, Charlotte Teunissen, Lucilla Parnetti, Markus Otto)

starting from 19.30 Evening program of the society

Friday July 1st

- 08.30 – 10.00 Highlights from poster session + data blitz
Lucilla Parnetti, Italy, Markus Otto, Germany
- 10.00 – 10.30 **Coffee break**
- 10.30 – 12.10 **Symposium – Biomarkers for psychiatric disorders, promise or hope?**
Chairs: Alberto Lleo (Spain), Piotr Lewczuk (Germany)
- 10.30 – 10.50 Biomarkers in Psychiatric diseases: Giulia Menculini (Italy)
Talk: based on abstract selection
- 11.50 – 12.00 Thimet Oligopeptidase is a potential CSF biomarker for Alzheimer's Disease:
Yanaika Hok-A-Hin (Netherlands)
- 12.00 – 12.10 A panel of CSF proteins separates genetic frontotemporal dementia from
presymptomatic mutation carriers: a GENFI study: Sofia Bergstrom (Sweden)
- 12.10 – 13.15 **Lunch break**
- 13.15 – 14.25 **Novel technologies**
Chairs: Armand Perret Liaudet (France), Koen Poesen (Belgium)
- 13.15 – 13.25 Blood levels of Beta-Synuclein are increased in adults with Down syndrome and
precede elevation of pTau181: Patrick Oeckl (Germany)
- 13.25 – 13.35 CSF phosphorylated-tau species and total-tau in different neurodegenerative
diseases measured by mass spectrometry: Laia Montoliu-Gaya (Sweden)
- 13.35 – 13.55 Company: Single-molecule array (Simoa®) for ultrasensitive measurement of
neurological biomarkers in blood" (Paula Perin, Quanterix)
- 13.55 – 14.15 Company: Fujirebio – title: to be announced
- 14.15 – 14.35 Company: Roche – title: to be announced
- 14.35 – 15.00 **Keynote**
Chairs: Catharina Groß (Germany), Hayrettin Tumani (Germany)
- Sylvain Lehmann (France) – Mass Spec: road towards clinics?**
- 15.00 – 15.10 **Closing remarks**
Markus Otto (Germany)
- 15.10 Farewell

Registration:

Please register via e-mail to our secretary Sandra Langner (registration-CSF-society-meeting@neurochem.info)

If you need special dietary restrictions (vegetarian, etc.), please let us know.

Fees:

Attendance fee: 200EUR (students)

Attendance fee: 280EUR (non members)

Attendance fee: 250EUR (members)

Attendance fee: 350EUR (company employees)

Please transfer the attendance fee before the meeting. This is especially necessary, if you want to present a poster.

Bank detail:

Account holder: University hospital Ulm

Bank: Sparkasse Ulm

Swift Code: SOLADES1ULM

IBAN: DE16 6305 0000 0000 1064 78

reason for transfer: D.5288 - CSF meeting

Abstracts:

Due to limited space, we can only offer places for **100** posters. Selection is based on quality. Please send us a structured abstract (background, question, methods, results, conclusions, not more than 350 words). Please make sure, that you indicate the corresponding author (make sure, that you registered for the meeting). **We have some rare places for posters left.**

Send the abstract as pdf or doc-file to:

abstract-submission-CSF-society-meeting@neurochem.info

Local organization committee:

Markus Otto, Halle (Saale)

Hayrettin Tumani, Ulm

Klemens Ruprecht, Berlin